Raymond Deshaies

Dr. Deshaies has directed basic and applied research programs for over 30 years, first as a professor and Howard Hughes Investigator at Caltech, and subsequently as the head of global research at Amgen. While at Caltech he co-conceived/developed proof-of-prinicple (with Craig Crews, Yale) for targeted protein degradation with PROTACs and co-founded two companies, one of which discovered and developed Kyprolis carfilzomib. His fundamental research at Caltech was recognized by election to the US National Academy of Sciences in 2016 and his applied research with Dr. Crews has been jointly honored by the Gabbay Award in 2023 and Passano Award in 2025. While leading global research at Amgen, his team advanced nearly 5 dozen clinical candidates, including Lumakras sotorasib, olpasiran, MariTide, xaluritamig, and AMG193.